Latest news with #BeiGene
Globe and Mail
15-07-2025
- Business
- Globe and Mail
Follicular Lymphoma Market Forecast 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Revenue, Statistics, Prevalence and Companies by DelveInsight
Follicular Lymphoma Market Growth Accelerates at a CAGR of 6% During the Forecast Period (2025-2034). Increased awareness of the disease has led to a higher number of treated cases, contributing to market growth. The rising number of clinical trials focused on follicular lymphoma are a significant driver of its market's expansion. Follicular Lymphoma Companies are Roche, BeiGene, Kite Pharma, Incyte Corp, AstraZeneca, Abbvie, Novartis, Innovent Biologics, Regeneron, Genentech, Eli Lilly, more. (Albany, USA) DelveInsight's " Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast-2034 ' report offers an in-depth understanding of the Follicular Lymphoma, historical and forecasted epidemiology as well as the Follicular Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The Follicular Lymphoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Follicular Lymphoma market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Follicular Lymphoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Follicular Lymphoma market. Key highlights of the Follicular Lymphoma Market Report: The Follicular Lymphoma market size was valued ~USD 1,082 million in 2024 and is anticipated to grow with a significant CAGR during the study period (2020-2034) In February 2025, Regeneron Pharmaceuticals announced the resubmission of the Biologics License Application (BLA) for odronextamab in relapsed/refractory follicular lymphoma to the FDA. The company expects a decision from the FDA in the second half of 2025. In February 2025, Genmab A/S (Nasdaq: GMAB) announced that the Japan Ministry of Health, Labour, and Welfare has approved EPKINLY Registered (epcoritamab) for treating patients with relapsed or refractory follicular lymphoma (FL; Grades 1 to 3A) who have undergone two or more prior treatments. This approval makes EPKINLY the first and only subcutaneously administered T-cell engaging bispecific antibody approved in Japan for both relapsed or refractory FL and large B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and primary mediastinal large B-cell lymphoma, after two or more prior therapies. In January 2025, CRISPR Therapeutics announced plans to collaborate with regulatory authorities to determine the next steps for CTX112 in B-cell malignancies, with an update anticipated by mid-2025. In September 2024, The FDA granted Priority Review status to the Biologics License Application (BLA) for odronextamab, intended for the treatment of adults with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma (DLBCL) who have not responded to at least two prior systemic therapies. In 2024, approximately 35,000 cases of follicular lymphoma were diagnosed across the 7MM. In 2024, the United States generated around USD 1,082 million in revenue. In 2024, Germany represented the largest market size among the EU4 and the UK, with an estimated value of around USD 108 million. In 2024, Spain had the smallest market size among the EU4 and the UK, with an estimated value of around USD 61 million. In 2024, the United States had the highest number of Follicular Lymphoma cases among the 7MM, with approximately 17,000 cases. This number is expected to rise by 2034. In 2024, the 60-80 age group had the highest incidence of follicular lymphoma, with around 9,000 cases, followed by the 40-59 age group with approximately 4,000 cases. In 2024, stage IV follicular lymphoma cases accounted for approximately 34% of all cases. In 2024, the incidence of follicular lymphoma in the EU4 and the UK was approximately 14,000, with Germany reporting the highest number of cases. Key Follicular Lymphoma Companies: Roche, BeiGene, Kite Pharma, Incyte Corporation, AstraZeneca, Xynomic Pharmaceuticals, MEI Pharma, Novartis, Innovent Biologics, Regeneron, Genentech, Xynomic Pharma, Eli Lilly and Company, ADC Therapeutics S.A, BeiGene, Cephalon, Epizyme, Inc., Pharmacyclics LLC., Gemin X, AbbVie, Millennium Pharma, and others Key Follicular Lymphoma Therapies: LUNSUMIO (mosunetuzumab), BRUKINSA (zanubrutinib), YESCARTA, MONJUVI (tafasitamab), AZD0486, Abexinostat, ME-401, Tisagenlecleucel, Parsaclisib (IBI376), Odronextamab, Mosunetuzumab, Abexinostat, Rituximab IV, Atezolizumab (MPDL3280A) [TECENTRIQ], Enzastaurin, Loncastuximab tesirine, Zanubrutinib, Bendamustine, Tazemetostat, ibrutinib, Obatoclax mesylate, Ibrutinib, IXAZOMIB, and others The Follicular Lymphoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Follicular Lymphoma pipeline products will significantly revolutionize the Follicular Lymphoma market dynamics. Follicular Lymphoma Overview Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma that arises from B-lymphocytes, a type of white blood cell essential for the immune system. Follicular Lymphoma typically originates in the lymph nodes but can also affect the bone marrow and spleen. This form of lymphoma is characterized by the formation of abnormal follicles within lymph nodes, leading to painless swelling, fatigue, night sweats, and unexplained weight loss. Follicular Lymphoma most commonly affects adults over the age of 60 and is usually diagnosed through a combination of physical examination, blood tests, imaging studies, and biopsy. Genetic testing may also be used to identify specific mutations, such as the BCL2 gene rearrangement, which is often associated with this disease. Follicular Lymphoma treatment options vary depending on the stage and symptoms, ranging from active surveillance in early stages to targeted therapies, immunotherapy, chemotherapy, and radiation therapy in more advanced or symptomatic cases. While Follicular Lymphoma is generally considered incurable, it is highly treatable, and many patients live for years with proper disease management. Follicular Lymphoma research continues to advance, with clinical trials exploring novel therapies aimed at improving outcomes and extending progression-free survival, making the future more hopeful for affected patients. Follicular Lymphoma Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Follicular Lymphoma Epidemiology Segmentation: The Follicular Lymphoma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into: Total Prevalence of Follicular Lymphoma Prevalent Cases of Follicular Lymphoma by severity Gender-specific Prevalence of Follicular Lymphoma Diagnosed Cases of Episodic and Chronic Follicular Lymphoma Download the report to understand which factors are driving Follicular Lymphoma epidemiology trends @ The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Follicular Lymphoma market or expected to get launched during the study period. The analysis covers Follicular Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Follicular Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Follicular Lymphoma Therapies and Key Companies LUNSUMIO (mosunetuzumab): Roche BRUKINSA (zanubrutinib): BeiGene YESCARTA: Kite Pharma MONJUVI (tafasitamab): Incyte Corporation AZD0486: AstraZeneca Abexinostat: Xynomic Pharmaceuticals ME-401: MEI Pharma Tisagenlecleucel: Novartis Parsaclisib (IBI376): Innovent Biologics Odronextamab: Regeneron Mosunetuzumab: Genetech Abexinostat: Xynomic Pharma Rituximab IV: Roche Atezolizumab (MPDL3280A) [TECENTRIQ]: Hoffmann-La Roche Enzastaurin: Eli Lilly and Company Loncastuximab tesirine: ADC Therapeutics S.A Zanubrutinib: BeiGene Bendamustine: Cephalon Tazemetostat: Epizyme, Inc. ibrutinib: Pharmacyclics LLC. Obatoclax mesylate: Gemin X Ibrutinib: AbbVie IXAZOMIB: Millennium Pharma To know more about Follicular Lymphoma companies working in the treatment market, visit @ Follicular Lymphoma Medication, Manufacturers and Therapeutic Assessment Follicular Lymphoma Market Outlook DelveInsight estimates that the US market size for follicular lymphoma is expected to grow from USD 1 billion in 2024 at a significant CAGR by 2034. The follicular lymphoma market is experiencing steady growth, driven by rising incidence rates, increasing awareness, and advancements in targeted therapies such as monoclonal antibodies and CAR-T cell treatments. The aging global population further contributes to market expansion. Additionally, ongoing clinical trials and approvals of novel agents are expected to boost market opportunities in the coming years. The anticipated launch of these emerging therapies for follicular lymphoma are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the follicular lymphoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. Scope of the Follicular Lymphoma Market Report Study Period: 2020-2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Follicular Lymphoma Companies: AbbVie (NYSE: ABBV), Genentech (subsidiary of Roche), Xynomic Pharma (OTC: XYNM), Regeneron (NASDAQ: REGN), Epizyme, Inc. (formerly NASDAQ: EPZM), ADC Therapeutics S.A (NYSE: ADCT), Kite Pharma (subsidiary of Gilead Sciences), Eli Lilly and Company (NYSE: LLY), Cephalon (acquired by Teva), Innovent Biologics (HKEX: 1801), Incyte Corporation (NASDAQ: INCY), Novartis (SWX: NOVN), MEI Pharma (NASDAQ: MEIP), AstraZeneca (LSE: AZN), BeiGene (NASDAQ: BGNE; HKEX: 6160), Millennium Pharma (subsidiary of Takeda), Roche (SWX: ROG), Gemin X (acquired by Cephalon), Pharmacyclics LLC. (formerly NASDAQ: PCYC), Xynomic Pharmaceuticals (OTC: XYNM), and others. Key Follicular Lymphoma Therapies: LUNSUMIO (mosunetuzumab), BRUKINSA (zanubrutinib), YESCARTA, MONJUVI (tafasitamab), AZD0486, Abexinostat, ME-401, Tisagenlecleucel, Parsaclisib (IBI376), Odronextamab, Mosunetuzumab, Abexinostat, Rituximab IV, Atezolizumab (MPDL3280A) [TECENTRIQ], Enzastaurin, Loncastuximab tesirine, Zanubrutinib, Bendamustine, Tazemetostat, ibrutinib, Obatoclax mesylate, Ibrutinib, IXAZOMIB, and others Follicular Lymphoma Therapeutic Assessment: Follicular Lymphoma current marketed and Follicular Lymphoma emerging therapies Follicular Lymphoma Market Dynamics: Follicular Lymphoma market drivers and Follicular Lymphoma market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Follicular Lymphoma Unmet Needs, KOL's views, Analyst's views, Follicular Lymphoma Market Access and Reimbursement Follicular Lymphoma Clinical Trials and FDA Approvals Table of Contents 1. Follicular Lymphoma Market Report Introduction 2. Executive Summary for Follicular Lymphoma 3. SWOT analysis of Follicular Lymphoma 4. Follicular Lymphoma Patient Share (%) Overview at a Glance 5. Follicular Lymphoma Market Overview at a Glance 6. Follicular Lymphoma Disease Background and Overview 7. Follicular Lymphoma Epidemiology and Patient Population 8. Country-Specific Patient Population of Follicular Lymphoma 9. Follicular Lymphoma Current Treatment and Medical Practices 10. Follicular Lymphoma Unmet Needs 11. Follicular Lymphoma Emerging Therapies 12. Follicular Lymphoma Market Outlook 13. Country-Wise Follicular Lymphoma Market Analysis (2020-2034) 14. Follicular Lymphoma Market Access and Reimbursement of Therapies 15. Follicular Lymphoma Market Drivers 16. Follicular Lymphoma Market Barriers 17. Follicular Lymphoma Appendix 18. Follicular Lymphoma Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
&w=3840&q=100)
Business Standard
24-06-2025
- Business
- Business Standard
Glenmark Pharma launches lung cancer treatment drug Tevimbra in India
Glenmark Pharmaceuticals on Tuesday said it has launched the lung cancer treatment drug Tevimbra in India, following the approval by the Central Drugs Standard Control Organisation. Tevimbra is developed by BeiGene (now BeOne Medicines), a global oncology leader. This launch marks Glenmark's first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio, the company said in a regulatory filing. "At a time when the cancer burden is rising sharply, we are proud to enable oncologists and patients to access Tevimbra, a therapy with proven efficacy and safety outcomes, strong science, and meaningful impact," Glenmark Pharmaceuticals President and Business Head India Formulations Alok Malik said. Immuno-oncology offers a promising future for the treatment of various types of advanced cancers, which are difficult to treat, he said, adding that "Our foray in this area marks a significant inflection point in our journey to build a world-class oncology portfolio that is innovative, inclusive and at the same time life-changing for patients". Tevimbra is indicated for the treatment of first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy and second-line treatment of locally advanced or metastatic NSCLC and oesophagal squamous cell carcinoma (ESCC) as monotherapy, the company said. It is approved and marketed in multiple leading global markets, including the United States, European Union, Australia and China. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Upturn
24-06-2025
- Business
- Business Upturn
Glenmark Pharmaceuticals launches TEVIMBRA in India for advanced lung and esophageal cancer treatment
By Aditya Bhagchandani Published on June 24, 2025, 09:50 IST Glenmark Pharmaceuticals has announced the launch of TEVIMBRA® (tislelizumab) in India, marking its entry into the immuno-oncology space. This anti-PD-1 monoclonal antibody, developed by global oncology firm BeiGene (now BeOne Medicines), is approved for the treatment of advanced non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma (ESCC). The drug is designed to restore T-cell function and minimize off-target immune suppression, having shown strong efficacy and safety in global trials. Already approved in over 46 countries including the U.S. and EU, TEVIMBRA has been used in treating more than 1.5 million patients worldwide. Glenmark's President Alok Malik stated that the company is committed to transforming cancer care in India by making cutting-edge immunotherapies accessible. The launch comes at a time when cancer incidence in India is sharply rising, especially NSCLC and ESCC which dominate their respective cancer types in the country. This milestone aligns with Glenmark's broader ambition to build a globally benchmarked oncology portfolio, adding to its existing focus areas of respiratory and dermatology. Disclaimer: This content is for informational purposes only and not a substitute for professional medical advice. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
&w=3840&q=100)
Business Standard
10-06-2025
- Business
- Business Standard
Glenmark Pharma rises 2% as company to launch blood cancer treatment drug
Glenmark Pharma share price rose 1.7 per cent in trade on Tuesday, June 10, 2025, logging an intraday high at ₹1,626.6 per share on BSE. At 10:30 AM, Glenmark Pharma shares were trading 1.56 per cent higher at ₹1,623.35 per share on the BSE. In comparison, the BSE Sensex was up 0.05 per cent at 82,482.52. The company's market capitalisation stood at ₹45,811.07 crore. Its 52-week high was at ₹1,830.05 per share and 52-week low was at ₹1,176 per share. In the past one year, Glenmark shares have gained 33 per cent as compared to Sensex's rise of around 8 per cent. What is boosting rally in Glenmark Pharma shares? The stock gained after the company announced the upcoming launch of zanubrutinib, under the brand name Brukinsa in India. Brukinsa, developed by global oncology company BeOne Medicines (formerly BeiGene), is an orally available Bruton's tyrosine kinase (BTK) inhibitor designed to treat multiple types of B-cell blood cancers. It is the first and only BTK inhibitor approved in India for five types of B-cell malignancies. According to the filing, Brukinsa has already been approved in more than 70 countries, with clinical efficacy demonstrated through trials such as ALPINE, ASPEN and SEQUOIA. Its entry into the Indian market addresses a critical need for new and effective blood cancer treatments. The drug offers a unique pharmacological profile with high response rates and durable disease control across multiple B-cell malignancies. It allows a flexible dosing schedule—once or twice daily—tailored to patient needs. In the ALPINE trial for relapsed or refractory chronic lymphocytic leukaemia (CLL), Brukinsa showed a lower incidence of serious cardiac side effects compared to ibrutinib, a widely used targeted therapy. Fewer patients discontinued Brukinsa due to heart-related complications. About Glenmark Pharmaceuticals Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. About BeOne Medicines BeOne Medicines, formerly known as BeiGene, is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide.
&w=3840&q=100)
Business Standard
09-06-2025
- Business
- Business Standard
Glenmark set to launch blood cancer treatment drug Brukinsa in India
Glenmark Pharmaceuticals Ltd, a global pharmaceutical company, is set to introduce zanubrutinib in India under the brand name Brukinsa, following approval from the Drugs Controller General of India (DCGI). Brukinsa, developed by global oncology company BeOne Medicines (formerly BeiGene), is an orally available Bruton's tyrosine kinase (BTK) inhibitor designed to treat multiple types of B-cell blood cancers. It is the first and only BTK inhibitor approved in India for five types of B-cell malignancies. Approved in over 70 countries Brukinsa has already been approved in more than 70 countries, with clinical efficacy demonstrated through trials such as ALPINE, ASPEN and SEQUOIA. Its entry into the Indian market addresses a critical need for new and effective blood cancer treatments. The drug offers a unique pharmacological profile with high response rates and durable disease control across multiple B-cell malignancies. It allows a flexible dosing schedule—once or twice daily—tailored to patient needs. In the ALPINE trial for relapsed or refractory chronic lymphocytic leukaemia (CLL), Brukinsa showed a lower incidence of serious cardiac side effects compared to ibrutinib, a widely used targeted therapy. Fewer patients discontinued Brukinsa due to heart-related complications. "We look forward to bringing Brukinsa to India in the coming months as part of our ongoing partnership with BeiGene (now BeOne Medicines)," said Alok Malik, President and Business Head – India Formulations, Glenmark Pharmaceuticals. 'This launch marks a significant milestone in our innovative oncology portfolio, offering patients in India access to a globally trusted therapy with proven efficacy and safety. It underscores Glenmark's ongoing commitment to providing effective and advanced treatments for patients with haematological malignancies," he added. Global partnership expands to India Adam Roach, Senior Vice President and Head of the Japan and Asia Pacific region at BeiGene, commented: 'The introduction of Brukinsa in India marks an important step in our ongoing mission to expand patient access to innovative oncology treatments across the Asia Pacific region.' 'We are proud to support Glenmark in bringing this therapy to patients in India, furthering our shared commitment to improve healthcare outcomes globally,' he said.
